Xenetic Biosciences is trading at $3.32, down 22.17%, in pre-market after announcing an all-stock reverse merger with Santersus AG on September 16, 2026.
- Existing shareholders are expected to own approximately 15% of the combined company, versus 85% for Santersus shareholders.
- The transaction requires shareholder approval and is expected to close in the fourth quarter of 2026.